Table 3 Association between amino acid levels, age, olanzapine equivalents and sex among healthy donors (A), ARMS (B), FEP (C) and SCZ (D) subjects.
From: Variations of blood D-serine and D-aspartate homeostasis track psychosis stages
Healthy donors | ||||
|---|---|---|---|---|
A | AA | Age; rho (p) | OLZ eq; rho (p) | Sex: M vs F: median (IQR); p |
L-Ser | −0.137 (0.145) | – | 114 (101–133) vs 124 (109–141); 0.112 | |
D-Ser | 0.010 (0.917) | – | 1.39 (1.14–1.79) vs 1.47 (1.03–1.91); 0.797 | |
D-Ser/Total | 0.082 (0.381) | – | 1.11 (0.96–1.43) vs 1.17 (0.93–1.39); 0.991 | |
L-Asp | 0.055 (0.561 | – | 15.0 (10.6–19.2) vs 14.2 (10.8–19.4); 0.613 | |
D-Asp | 0.106 (0.260) | – | 0.15 (0.08–0.31) vs 0.21 (0.07–0.33); 0.375 | |
D-Asp/Total | 0.096 (0.310) | – | 1.07 (0.42–2.08) vs 1.55 (0.44–2.24); 0.311 | |
L-Gln | −0.139 (0.139) | – | 376 (345–406) vs 330 (293–367); <0.001* | |
L-Glu | 0.081 (0.389) | – | 34.2 (24.9–52.2) vs 19.4 (12.0–34.3); <0.001* | |
L-Gln/L-Glu | −0.119 (0.206) | – | 10.1 (7.4–14.7) vs 16.5 (10.5–25.5); <0.001* | |
L-Asn | −0.141 (0.133) | – | 40.5 (35.4–47.0) vs 40.8 (33.2–47.1); 0.929 | |
Gly | −0.075 (0.425) | – | 203 (177–236) vs 197 (168–236); 0.687 | |
B | At Risk Mental State | |||
L-Ser | −0.260 (0.078) | – | 137 (119–153) vs 126 (95–146); 0.170 | |
D-Ser | −0.429 (0.003)* | – | 1.98 (1.66–2.28) vs 1.86 (1.01–2.08); 0.079 | |
D-Ser/Total | −0.250 (0.090) | – | 1.37 (1.06–1.85) vs 1.37 (1.03–1.61); 0.529 | |
L-Asp | 0.153 (0.305) | – | 11.9 (9.7–20.6) vs 11.3 (6.6–21.5); 0.244 | |
D-Asp | 0.160 (0.283) | – | 0.32 (0.20–0.45) vs 0.24 (0.18–0.41); 0.307 | |
D-Asp/Total | −0.005 (0.972) | – | 2.47 (1.65–3.15) vs 2.11 1.66–3.75); 0.975 | |
L-Gln | −0.028 (0.853) | – | 365 (326–399) vs 325 (261–398); 0.119 | |
L-Glu | 0.284 (0.053) | – | 24.8 (20.3–36.9) vs 15.5 (12.2–29.0); 0.029* | |
L-Gln/L-Glu | −0.290 (0.048)* | – | 14.1 (11.4–18.8) vs 18.0 (11.4–30.4); 0.148 | |
L-Asn | 0.031 (0.834) | – | 42.4 (36.9–48.0) 39.2 (31.1–48.2); 0.197 | |
Gly | −0.307 (0.036)* | – | 229 (189–261) vs 201 (157–250); 0.114 | |
C | First Episode Psychosis | |||
L-Ser | 0.215 (0.302) | −0.355 (0.124) | 132 (105–140) vs 116 (105–127); 0.388 | |
D-Ser | 0.235 0.259) | −0.158 (0.505) | 1.79 (1.53–2.27) vs 1.55 (1.17–1.81); 0.121 | |
D-Ser/Total | −0.069 (0.742) | 0.137 (0.564) | 1.36 (1.09–1.54) vs 1.21 (1.03–1.53); 0.522 | |
L-Asp | 0.311 (0.131) | −0.315 (0.176) | 15.6 (10.1–30.1) vs 14.3 (10.2–22.6); 0.522 | |
D-Asp | 0.582 (0.002)* | −0.199 (0.401) | 0.34 (0.28–0.82) vs 0.32 (0.25–0.53); 0.388 | |
D-Asp/Total | 0.050 (0.814) | 0.014 (0.954) | 2.44 (1.81–3.70) vs 2.64 (1.80–3.08); 0.890 | |
L-Gln | −0.166 (0.427) | 0.114 (0.631) | 317 (285–361) vs 319 (296–338); 0.934 | |
L-Glu | 0.634 (0.001)* | −0.014 (0.954) | 30.6 (23.7–50.3) vs 28.8 (20.3–41.5); 0.522 | |
L-Gln/L-Glu | −0.631 (0.001)* | 0.042 (0.859) | 10.8 (6.5–17.4) vs 12.8 (7.4–16.6); 0.637 | |
L-Asn | 0.202 (0.333) | −0.023 (0.922) | 42.7 (32.3–49.5) vs 36.1 (30.7–45.7); 0.388 | |
Gly | −0.019 (0.927) | −0.172 (0.468) | 223 (159–252) vs 172 (129–219); 0.169 | |
D | Schizophrenia | |||
L-Ser | 0.118 (0.292) | 0.101 (0.426) | 138 (119–168) vs 151 (138–182); 0.051 | |
D-Ser | 0.223 (0.044)* | 0.018 (0.887) | 1.40 (1.15–1.74) vs 1.33 (1.10–1.52); 0.426 | |
D-Ser/Total | 0.033 (0.766) | −0.071 (0.576) | 0.93 (0.76–1.47) vs 0.85 (0.74–0.98); 0.096 | |
L-Asp | 0.188 (0.091) | 0.133 (0.296) | 23.9 (17.4–31.1) vs 25.3 (17.6–35.1); 0.366 | |
D-Asp | 0.256 (0.020)* | 0.140 (0.270) | 0.21 (0.11–0.40) vs 0.17 (0.07–0.39); 0.404 | |
D-Asp/Total | 0.158 (0.155) | 0.076 (0.549) | 0.85 (0.43–2.05) vs 0.71 (0.31–1.62); 0.247 | |
L-Gln | −0.056 (0.617) | −0.104 (0.414) | 351 (294–396) vs 347 (325–383); 0.603 | |
L-Glu | 0.255 (0.021)* | 0.109 (0.392) | 88.1 (42.6–140.5) vs 75.6 (41.4–127.9); 0.966 | |
L-Gln/L-Glu | −0.281 (0.010)* | −0.128 (0.313) | 4.13 (2.57–7.59) vs 4.50 (2.76–8.88); 0.848 | |
L-Asn | 0.144 (0.198) | 0.098 (0.442) | 45.4 (34.3–52.4) vs 43.4 (38.3–56.7); 0.603 | |
Gly | 0.171 (0.124) | −0.077 (0.544) | 241 (195–285) vs 292 (222–338); 0.014* | |
